Vaccine plus immunotherapy for unresectable liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and sign informed consent
- Have liver cancer (hepatocellular carcinoma) confirmed by biopsy or surgery
- Have cancer that is advanced and cannot be fully removed with surgery (unresectable) and can be measured on scans
- Have not had any prior whole-body (systemic) anti-cancer treatment
- Have good liver function (Child-Pugh Class A) and limited overall disability (performance status less than 2)
- Have not had prior immune therapy for cancer (like anti–PD-1, anti–PD-L1, or anti–CTLA4)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.